Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049305 | 0.86 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL6371421 | 0.84 | CNR2 (0.34) | PIK3CG | |
| SCHEMBL18997069 | 0.79 | PIK3CG (0.34) | PIK3CGRAB9ATP53KLF5SMN1; SMN2 | |
| SCHEMBL16544514 | 0.79 | SMN1; SMN2 (0.41) | PIK3CGRAB9ALMNATP53KLF5 | |
| SCHEMBL1785672 | 0.77 | PIK3CG (0.37) | PIK3CGRAB9ATP53KLF5SMN1; SMN2 | |
| SCHEMBL2608946 | 0.76 | MAPT (0.44) | SORT1AAK1NAMPTRAB9ANR2F2 | |
| SCHEMBL23222124 | 0.76 | PPARA (0.38) | PIK3CGRAB9ALMNATP53KLF5 | |
| SCHEMBL15945547 | 0.76 | CNR1 (0.33) | PIK3CGRAB9ATP53KLF5SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3712081 | 0.76 | PIK3CG (0.36) | PIK3CGRAB9ATP53KLF5SMN1; SMN2 | |
| SCHEMBL22576485 | 0.75 | SORT1 (0.39) | SORT1AAK1NAMPTRAB9ANR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | SORT1 4185/4885AAK1 337/4885NAMPT 373/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | SORT1 4113/4885AAK1 478/4885NAMPT 440/4885 |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | SORT1 4655/4885AAK1 3260/4885NAMPT 218/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | SORT1 4655/4885AAK1 3260/4885NAMPT 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.